Siegfried Holding AG

Siegfried Holding AG, headquartered in Zofingen, Switzerland, is a globally leading Contract Development and Manufacturing Organization (CDMO) that has been serving the pharmaceutical industry since 1873. With a rich heritage spanning over 150 years, Siegfried has evolved into a premier partner for both major pharmaceutical and dynamic biotechnology companies worldwide. The company uniquely combines both drug substance (Active Pharmaceutical Ingredients – APIs) and drug product (finished dosage forms) manufacturing capabilities under one roof, offering an integrated, end-to-end supply chain solution from early-stage development to commercial-scale production.

Siegfried operates a global network of advanced manufacturing facilities across Europe, the United States, and Asia, ensuring proximity to key markets and robust supply chain resilience. The organization is highly regarded for its technological prowess in handling complex and hazardous chemical syntheses, including highly potent APIs (HPAPIs), controlled substances, and complex bioconjugations.

In the drug product segment, Siegfried offers comprehensive services ranging from oral solid dosage forms to complex sterile injectables, utilizing state-of-the-art aseptic fill-and-finish technologies. Their R&D teams are heavily invested in process optimization, continuous manufacturing, and innovative formulation technologies, ensuring that client molecules are transitioned smoothly from clinical trials to the market.

The company’s unwavering commitment to quality is reflected in its stellar regulatory track record, maintaining approvals from stringent authorities like the US FDA, EMA, and Swissmedic. Siegfried’s strategic vision focuses on long-term partnerships, sustainability, and continuous technological advancement, making it an indispensable pillar in the global healthcare ecosystem.